Lastly, when PRLR-DbsAb was delivered in combination with a PD-1 antibody, anti-tumor activity was enhanced against MDA-MB-231 cells supporting the rationale of targeting PRLR with the novel BsAbs technology for PRLR-expressing breast cancers (97). This evidence concerns the gene PRLR and breast carcinoma.